Pfizer (PFE), which became a household name during the pandemic with its COVID-19 vaccine, has since been struggling. PFE has lost over half of its market cap since peaking in late 2021, and is just barely positive for 2024.
Pfizer’s woes are not hard to understand, as sales of its COVID-19 vaccine, Comirnaty, and the Paxlovid pill have cratered - and unsurprisingly so. The future trajectory of these products, whose sales skyrocketed during the COVID-19 pandemic, also looks shaky.
